Matthew S. Schonholz

Matthew S. Schonholz

Matthew Schonholz is a partner in the Los Angeles office of Munger, Tolles & Olson.

Mr. Schonholz specializes in tax and executive compensation law, with a focus on mergers and acquisitions, private equity and debt investments, public securities offerings, joint ventures and investment fund formation. 

He has substantial experience advising and representing founders, C-suite executives, management teams and portfolio managers in compensation and employment arrangements relating to public and private companies and private equity and hedge funds.

He regularly counsels public and private companies, investment fund sponsors, and boards of directors in the tax structuring and documentation of mergers, equity and asset acquisitions and dispositions, private equity, real estate, direct lending and hedge fund formations, joint ventures and operating partnerships, and transactions involving S corporations, partnerships, LLCs and disregarded entities.

Mr. Schonholz was previously a tax associate at a leading international law firm. He also previously held positions as a transaction tax consultant at a “Big-4” accounting firm and a litigator at a boutique law firm.

Before entering private practice, Mr. Schonholz clerked for Judges Nora M. Manella and Dikran Tevrizian of the U.S. District Court for the Central District of California.

In addition to his legal practice, Mr. Schonholz has been an adjunct professor of law at Loyola Law School Los Angeles.


Representative Matters*

Private Equity

  • Represented the senior executives of Kayne Anderson Real Estate in respect of Goldman Sachs Asset Management Petershill Platform’s minority investment in Kayne Anderson Real Estate.
  • Apollo Global Management in its $2.6 billion acquisition of publicly traded Aspen Insurance Holdings.
  • An investor group led by investment funds managed by affiliates of Apollo Global Management, LLC in its $1.4 billion acquisition of 40.6 percent of OneMain Holdings, Inc. from affiliates of Fortress Investment Group LLC.
  • Investment funds affiliated with Siris Capital Group, LLC in the:
    • $654 million acquisition of Xura, Inc. (formerly Comverse).
    • $500 million acquisition of Mitel Mobility Inc. (renamed Mavenir Systems, Inc.).
  • Nexus Capital Partners in its acquisition of FTD in a 363 sale.


  • Berkshire Hathaway in its:
    • commitment to invest $10 billion in Occidental Petroleum to finance Occidental’s proposed acquisition of Anadarko Petroleum.
    • issuance and sale of a $1.25 billion 4.25% investment grade senior notes offering due 2049.
  • Ken Lin (co-founder and CEO of Credit Karma, Inc.) in the sale of Credit Karma to Intuit Inc. for $8.1 billion in cash and stock.  
  • Intel Corporation in its agreement to sell its NAND flash memory solid state drive and wafer businesses to SK Hynix for $9 billion.
  • The special committee of Pope Resources’ board of directors in the acquisition by Rayonier Inc.
  • J. Paul Getty Trust in leading a consortium of foundations in the acquisition of the priceless photographic archive of Ebony and Jet magazines at auction.
  • Roche in its acquisitions of:
    • Ignyta, Inc., a cancer therapy company, for $1.7 billion in cash.
    • ForSight VISION4, a privately held biotechnology company focusing on drug delivery for treatment of retinal diseases.
    • Genia Technologies, a DNA sequencing company, for $125 million in cash and up to $225 million in milestones.
    • GeneWEAVE BioSciences, clinical microbiology diagnostics solutions company, for up to $425 million.
  • Genentech in its acquisition of Seragon Pharmaceuticals, Inc., a biotechnology company focused on the treatment of breast cancer, for up to $1.725 billion in cash.
  • IPC Healthcare in its acquisition by Team Health Holdings for $1.6 billion.
  • Medivation in its acquisition of worldwide rights to the breast cancer treatment, talazoparib, from BioMarin Pharmaceutical for cash consideration of up to $570 million.
  • Omnicell in its acquisition of Aesynt, a leading provider of medication and supply management solutions, for $275 million.

*Includes representations prior to Mr. Schonholz’s affiliation with Munger, Tolles & Olson.